High - and low-dose combination OCs decrease the risk of Endometrial cancer by 60% after at least 10 years of use Ovarian cancer by about 50% after 5 years of use and 80% after ≥ 10 years of use They also decrease the risk of functional ovarian cysts, benign ovarian tumors, abnormal uterine bleeding due to ovulatory dysfunction, dysmenorrhea, premenstrual dysphoric disorder, iron deficiency anemia, and benign breast disorders.